Supernus Pharmaceuticals, Inc. (SUPN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 32.81 |
| Open | 32.00 |
| Bid | 26.00 x 1000 |
| Ask | 35.56 x 900 |
| Day's Range | 30.55 - 32.99 |
| 52 Week Range | 23.15 - 34.50 |
| Volume | |
| Avg. Volume | 374,441 |
| Market Cap | 1.72B |
| Beta (5Y Monthly) | 1.05 |
| PE Ratio (TTM) | 25.32 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SUPN
Related Research
- Supernus Pharmaceuticals, Inc.SUPN: Lowering target price to $29.00SUPERNUS PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $29.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.RatingFair ValueEconomic Moatlast monthArgus Research
- GlobeNewswire
Supernus Announces Second Quarter 2022 Financial Results
Second quarter 2022 total revenues of $170.1 million, a 20% increase compared to second quarter 2021Second quarter 2022 GAAP operating earnings of $11.3 million; second quarter 2022 non-GAAP operating earnings of $37.6 millionQelbree® continued its growth trajectory, with 62,938 prescriptions in second quarter 2022, a 33% increase compared to first quarter 2022Second quarter 2022 Qelbree net product sales of $11.1 million increased 34% compared to first quarter of 2022; First six months 2022 Qel
- GlobeNewswire
Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
ROCKVILLE, Md., July 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2022 after the market closes on Thursday, August 4, 2022. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conferenc
- GlobeNewswire
Supernus to Participate in the Jefferies Healthcare Conference
ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 10:30 a.m. ET. Investors interested in arranging a meeting with company management should contact th
